

ACCESS-LA: Accelerating Community-Centered Equitable Scale-Up of Long-Acting PrEP

Project Summary

Area/Type: ACC

Sponsor/Support: OCB

Length/Project Status: 3 years; ONGOING



TRANSFORMATIONAL
INVESTMENT
CAPACITY

Problem

Long-acting injectable PrEP (LA-PrEP, prioritizing **lenacapavir**) can transform HIV prevention but **access is seriously jeopardized** by restrictive licensing, unaffordable pricing, and a decrease in funding. Without coordinated and timely action, LEN could remain inaccessible to those who need it most.

Proposed Solution

The ACCESS-LA project aims at improving access to LA-PrEP by implementing a multipronged approach that **integrates civil society-led advocacy, targeted support to MSF operations to introduce LA-PrEP through community-led service delivery models, and evidence generation to inform policy decisions** and sustainable scale-up for key and vulnerable populations.



Potential Impact

- Transforms HIV prevention delivery through **LA-PrEP introduction and implementation of community-based models of care for prevention**, tailored to various vulnerable populations.
- **Achieves policy and legal progress on LEN licensing, pricing, and registration**, leveraging operational evidence and community pressure.

Viability

- Builds on MSF programmes across three country clusters that reflect different access barriers
- Leverages strong partnerships with civil society organizations (CSOs) active in global and country-level advocacy,

Risk Mitigation

- Adopts a **phased implementation approach** as a core risk-mitigation strategy
- Defines **clear criteria to guide decision-making on progression from one phase to the next.**

Scalability

- Plans to develop adaptable toolkits, training materials, and operational guidance to **support replication across MSF.**
- Plans to engage Ministries of Health, Country Coordination Mechanisms (CCMs), donors, and governments to **embed LA PrEP in national plans and financing.**